Diet for the Maintenance of Weight Loss and Metabolic Health in Obese Postmenopausal Women

NCT04136093 | Unknown

• 1 other identifier: 445446
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study will be comparing the effectiveness of two diets: moderate in fat with a high proportion of monounsaturated fatty acids (MUFAs) - the Mediterranean diet (MED) and 2) the low in fat and high in dietary fiber contents the dietary approaches to stop hypertension diet (DASH) on weight maintenance and cardiovascular risks following a recent body weight reduction in centrally obese postmenopausal women. The tested diets will be given ad libitum manner. Moreover, adherence to both prescribed weight-loss maintenance diets will be also evaluated by the plasma concentration of alkylresorcinols (AR) as a possible whole grain wheat/rye dietary biomarker and by the analysis of fatty acids profile in erythrocyte membranes as a dietary biomarker of a fatty acids consumption. The participants of this study will be 150 non-smoking, postmenopausal women with central obesity, who wished to lose weight and have at least one other criterion of metabolic syndrome. The intervention will include 3 phases: Phase I (weeks 1-8), weight loss dietary intervention with 700 kcal/d energy deficit, Phase II (week 9-32), weight loss maintenance intervention for those participants losing ≥10% initial body weight the MED or the DASH diet will be offered in a random manner. The control group will receive oral dietary recommendations based on the Harvard model "Healthy Eating Plate". After this 32 weeks period will be finished, the participants will be discharged to the community with no contact by study personnel, until the 52-weeks follow-up period (Phase III).

Conditions

Metabolic Syndrome; Diet Modification; Postmenopause

Keywords

Weight Loss Maintenance; Metabolic Disorders; Postmenopausal Women; Cardiometabolic Parameters; Diet Therapy; Metabolic Syndrome

Outcome Measures

Primary Outcomes (8)

• Changes in body weight [kg]

  Changes in body weight from 9 to 52 week of weight loss maintenance period

  measurements will be taken after 8 weeks of weight loss diet (before weight loss maintenance period) and after 12, 16, 20, 24, 28, 32 and after 52 week of study.

• Changes in waist circumferences (WC) [cm]

  Changes in waist circumferences from 9 to 52 week of weight loss maintenance period.

  measurements will be taken after 8 weeks weight loss diet (before weight loss maintenance period) and after 12, 16, 20, 24, 28, 32 and after 52 week of study.

• Changes in fat mass [kg]

  Changes in fat mass from 9 to 52 weeks of weight loss maintenance period.

  measurements will be taken after 8 weeks weight loss diet (before weight loss maintenance period) and after 12, 16, 20, 24, 28, 32 and after 52 week of study.

• Changes in HDL cholesterol [mg/dL]

  Changes in HDL cholesterol from 9 to 52 week of weight loss maintenance period.

  Examination will be taken after 8 weeks weight loss diet (before weight loss maintenance period) after 32 and also after 52 week of study.

• changes in triglycerides (TG) [mg/dL]

  Changes in TG from 9 to 52 week of weight loss maintenance period.

  Examination will be taken after 8 weeks weight loss diet (before weight loss maintenance period) after 32 and also after 52 week of study.

• changes in glucose (GLU)

  Changes in GLU from 9 to 52 week of weight loss maintenance period.

  Examination will be taken after 8 weeks weight loss diet (before weight loss maintenance period) after 32 and 52 week of study.

• Changes in systolic blood pressure (SBP)

  Changes in SBP from 9 to 52 week of weight loss maintenance period.

  measurements will be taken after 8 weeks weight loss diet (before weight loss maintenance period) and after 12, 16, 20, 24, 28, 32 and also after 52 week of study.

• Changes in diastolic blood pressure (DBP)

  Changes in DBP from 9 to 52 weeks of weight loss maintenance period.

  measurements will be taken after 8 weeks weight loss diet (before weight loss maintenance period) and after 12, 16, 20, 24, 28, 32 and also after 52 week of study.

Secondary Outcomes (4)

• Physical activity level (PAL)

  The assessment of the PA level will be done after 8 weeks of weight loss diet (before weight loss maintenance period) and after 32 and 52 week of study.

• Eating behaviour (by measurement of dietary restraint, disinhibition and hunger)

  The assessment of the eating behaviour will be done after 8 weeks of weight loss diet (before weight loss maintenance period), after 32 and also after 52 week of study.

• Adherence to the prescribed diets (assessment of the plasma AR levels and concentration and fatty acids in red blood cells)

  The assessment of the adherence will be done after 12, 16, 20, 24, 28 and 32 week of study.

• Dietary intake

  Each participant"s dietary records will be assessed after 12, 16, 20, 24, 28, and 32 and also after 52 week of study.

Study Arms (3)

the MED

EXPERIMENTAL

The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group

Other: the MED

the DASH

EXPERIMENTAL

The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group

Other: the DASH

The control group

EXPERIMENTAL

The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.

Other: Control diet

Interventions

the MED OTHER

The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.

the MED

the DASH OTHER

The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.

the DASH

Control diet OTHER

The control group will only receive oral dietary recommendations based on the Harvard model "Healthy Eating Plate", that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal.

The control group

Eligibility Criteria

• Age: 50 Years - 65 Years
• Gender Eligibility Details: Postmenopausal women, with the absence of menses of over 12 months or serum follicle stimulating hormone \> 30 IU/mL.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• postmenopausal women, with the absence of menses of over 12 months or serum follicle stimulating hormone \> 30 IU/mL;
• with central obesity waist circumference (WC) ≥ 80 cm
• with low physical activity (PAL = 1,40);
• who wished to lose weight and weight loss maintenance;
• and have at least one other criterion of metabolic syndrome increased systolic blood pressure ≥ 130 mm Hg or high blood pressure diastolic ≥ 85 mm Hg or ongoing treatment of previously diagnosed hypertension, increased serum triglyceride levels above \>150 mg/dl (1.7 mmol/l) or ongoing therapy hypertriglyceridemia, decreased HDL cholesterol below than \<50 mg/dl (1.3 mmol/l), and fasting blood glucose \> 100 mg/dl (5.6 mmol / l) or ongoing treatment of previously diagnosed type 2 diabetes.

You may not qualify if:

• thyroid disease (hypothyroidism, hyperthyroidism, thyroiditis);
• hypercortisolism, Cushing's syndrome;
• kidney diseases;
• type 1 diabetes;
• asthma treated with oral and injectable steroids;
• cancers; mental disorders;
• New York Heart Association (NYHA) Class III heart failure;
• as well as any drug is known to influence liver function;
• endocrine disorders;
• hormonal replacement therapy;
• significant weight change in the six months prior to the current study;
• impaired absorption of nutrients (celiac disease, inflammatory bowel disease);
• intolerance or food allergy to key components of the intervention diets;
• smoking
• excessive alcohol consumption (consumption of more than 2 alcohol units per day - one alcohol unit equals one bottle of beer (340 g) or one glass of wine (140 g) or one glass of spirits (42.5 g of 40% spirit).

Sponsors & Collaborators

• Poznan University of Life Sciences: lead

Study Sites (1)

Poznan University of Life Science

Poznan, 60-624, Poland

RECRUITING

Related Publications (19)

• Bajerska J, Chmurzynska A, Muzsik A, Krzyzanowska P, Madry E, Malinowska AM, Walkowiak J. Weight loss and metabolic health effects from energy-restricted Mediterranean and Central-European diets in postmenopausal women: A randomized controlled trial. Sci Rep. 2018 Jul 24;8(1):11170. doi: 10.1038/s41598-018-29495-3.

  PMID: 30042488 BACKGROUND

• Beavers DP, Beavers KM, Lyles MF, Nicklas BJ. Cardiometabolic risk after weight loss and subsequent weight regain in overweight and obese postmenopausal women. J Gerontol A Biol Sci Med Sci. 2013 Jun;68(6):691-8. doi: 10.1093/gerona/gls236. Epub 2012 Nov 26.

  PMID: 23183902 BACKGROUND

• Beunza JJ, Toledo E, Hu FB, Bes-Rastrollo M, Serrano-Martinez M, Sanchez-Villegas A, Martinez JA, Martinez-Gonzalez MA. Adherence to the Mediterranean diet, long-term weight change, and incident overweight or obesity: the Seguimiento Universidad de Navarra (SUN) cohort. Am J Clin Nutr. 2010 Dec;92(6):1484-93. doi: 10.3945/ajcn.2010.29764. Epub 2010 Oct 20.

  PMID: 20962161 BACKGROUND

• Elfhag K, Rossner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes Rev. 2005 Feb;6(1):67-85. doi: 10.1111/j.1467-789X.2005.00170.x.

  PMID: 15655039 BACKGROUND

• FOLCH J, LEES M, SLOANE STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497-509. No abstract available.

  PMID: 13428781 BACKGROUND

• Gibson AA, Sainsbury A. Strategies to Improve Adherence to Dietary Weight Loss Interventions in Research and Real-World Settings. Behav Sci (Basel). 2017 Jul 11;7(3):44. doi: 10.3390/bs7030044.

  PMID: 28696389 BACKGROUND

• Hedrick VE, Dietrich AM, Estabrooks PA, Savla J, Serrano E, Davy BM. Dietary biomarkers: advances, limitations and future directions. Nutr J. 2012 Dec 14;11:109. doi: 10.1186/1475-2891-11-109.

  PMID: 23237668 BACKGROUND

• Hernaez A, Castaner O, Elosua R, Pinto X, Estruch R, Salas-Salvado J, Corella D, Aros F, Serra-Majem L, Fiol M, Ortega-Calvo M, Ros E, Martinez-Gonzalez MA, de la Torre R, Lopez-Sabater MC, Fito M. Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals: A Randomized Controlled Trial. Circulation. 2017 Feb 14;135(7):633-643. doi: 10.1161/CIRCULATIONAHA.116.023712.

  PMID: 28193797 BACKGROUND

• Kozakowski J, Gietka-Czernel M, Leszczynska D, Majos A. Obesity in menopause - our negligence or an unfortunate inevitability? Prz Menopauzalny. 2017 Jun;16(2):61-65. doi: 10.5114/pm.2017.68594. Epub 2017 Jun 30.

  PMID: 28721132 BACKGROUND

• Krishnan S, Cooper JA. Effect of dietary fatty acid composition on substrate utilization and body weight maintenance in humans. Eur J Nutr. 2014 Apr;53(3):691-710. doi: 10.1007/s00394-013-0638-z. Epub 2013 Dec 22.

  PMID: 24363161 BACKGROUND

• Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009 Feb 26;360(9):859-73. doi: 10.1056/NEJMoa0804748.

  PMID: 19246357 BACKGROUND

• Santoro N. The menopausal transition. Am J Med. 2005 Dec 19;118 Suppl 12B:8-13. doi: 10.1016/j.amjmed.2005.09.008.

  PMID: 16414322 BACKGROUND

• Soeliman FA, Azadbakht L. Weight loss maintenance: A review on dietary related strategies. J Res Med Sci. 2014 Mar;19(3):268-75.

  PMID: 24949037 BACKGROUND

• Stachowiak G, Pertynski T, Pertynska-Marczewska M. Metabolic disorders in menopause. Prz Menopauzalny. 2015 Mar;14(1):59-64. doi: 10.5114/pm.2015.50000. Epub 2015 Mar 25.

  PMID: 26327890 BACKGROUND

• Thom G, Lean M. Is There an Optimal Diet for Weight Management and Metabolic Health? Gastroenterology. 2017 May;152(7):1739-1751. doi: 10.1053/j.gastro.2017.01.056. Epub 2017 Feb 15.

  PMID: 28214525 BACKGROUND

• Desroches S, Lapointe A, Ratte S, Gravel K, Legare F, Turcotte S. Interventions to enhance adherence to dietary advice for preventing and managing chronic diseases in adults. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008722. doi: 10.1002/14651858.CD008722.pub2.

  PMID: 23450587 BACKGROUND

• Yannakoulia M, Kontogianni M, Scarmeas N. Cognitive health and Mediterranean diet: just diet or lifestyle pattern? Ageing Res Rev. 2015 Mar;20:74-8. doi: 10.1016/j.arr.2014.10.003. Epub 2014 Oct 18.

  PMID: 25461244 BACKGROUND

• Alhassan S, Kim S, Bersamin A, King AC, Gardner CD. Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond). 2008 Jun;32(6):985-91. doi: 10.1038/ijo.2008.8. Epub 2008 Feb 12.

  PMID: 18268511 BACKGROUND

• Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013 Apr;35(2):121-6. doi: 10.4103/0253-7176.116232.

  PMID: 24049221 BACKGROUND

MeSH Terms

Conditions

Metabolic Syndrome; Metabolic Diseases

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Nutritional and Metabolic Diseases

Study Officials

• Lidia Małczak, MSc

  Poznań University of Life Sciences

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lidia Małczak, MSc

CONTACT

+48787656850; lidia.malczak@up.poznan.pl

Joanna Bajerska, Prof.

CONTACT

+48618466056; joanna.bajerska@up.poznan.pl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 21, 2019
• First Posted: October 23, 2019
• Study Start: February 29, 2020
• Primary Completion: May 1, 2022
• Study Completion: September 1, 2022
• Last Updated: April 9, 2020

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will not share

Locations

PL (1)